UPDATE BELOW:
The U.S. Food and Drug Administration sent a warning letter to Compass International Innovations Inc., a manufacturer of stereotactic position systems and CT stereotactic adaptation systems, in late May. Compass International is based in Rochester, Minnesota and in addition to making these image-guided surgical systems, it sells biopsy needles and surgical arms among other products.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
The letter charges the company with four violations including:
- failure to establish and maintain procedures for software validation related to those stereotactic systems
- failure to properly identify and process customer complaints
- failure to conduct quality audits to assure that the system complies with the established quality system requirements
The warning letter also notes that so far, Compass has not provided enough information for the FDA to judge whether the company has taken the necessary corrective action. Compass had 15 days since it received the letter dated May 23 to respond.
Jon Rousu, Compass International’s president, wasn’t available for comment.
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
UPDATE – In a phone interview Thursday, Rousu said that the company has already responded to the warning letter and has corrected three of the four violations. The business hasn’t been affected by the warning letter so far, he said.